Novel Aspect of Androgen Action in Ovarian Cell Function and Dysfunction

雄激素在卵巢细胞功能和功能障碍中作用的新方面

基本信息

  • 批准号:
    10172961
  • 负责人:
  • 金额:
    $ 32.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary Our novel studies show that the androgen receptor (AR) and the modulator of AR action co-repressor COUPTF-II/NR2F2 are co-expressed in theca cells of mouse ovarian follicles and in theca cells of normal cycling and PCOS patients. Exposure of mice to androgens in vivo leads to marked changes in theca cell morphology and gene expression profiles, most notable of which is the marked induction of vascular cell adhesion molecular 1 (Vcam1). Recent provocative evidence that disruption of AR selectively in mouse theca cells prevents an androgen-mediated PCOS phenotype and the induction of Vcam1 provides key evidence for critical actions of AR in theca cells. Theca cells propagated from PCOS women express higher levels of VCAM1 and CYP17A1 than normal theca cells, further supporting the notion that elevated VCAM1 and androgens contribute to altered ovarian functions and dysfunctions in PCOS and hyperthecosis. Based on these compelling observations, we hypothesize that elevated androgens alter AR regulation of theca cell functions leading to specific changes in cellular and molecular events, including the induction of Vcam1, that underlie and/or contribute to ovarian dysfunction in PCOS and hyperthecosis. We propose to use genetically- modified mouse models, theca cells isolated from normal cycling and PCOS ovaries, and state-of-the-art molecular and cellular technologies to accomplish three Specific Aims. Specific Aim 1: Determine the cellular and molecular consequences of disrupting Ar, Nr2f2 or Vcam1 selectively in the mouse theca/stromal cells in vivo and in human theca cells from normal cycling and PCOS women in culture. Specific Aim 2: Determine the molecular and cellular events and responses to androgens that are altered when AR, NR2f2 or Vcam1 is selectively over-expressed in mouse and human theca/stromal cells. Specific Aim 3: Determine the molecular mechanisms by which androgens induce Vcam1 in theca cells and if inflammatory factors and cells are theca critical for VCAM1 expression Results of these studies will provide key new insights into how androgens, AR, NR2F2 and VCAM1 impact ovarian dysfunction by determining what cellular events and molecular pathways are altered selectively in theca cells by different levels of AR receptor activation. By combining powerful mutant mouse models and well-characterized human theca cells, new strategies for regulating androgen action and the consequences of androgen excess in women will be established and provide for novel diagnostic markers and therapeutic targets for PCOS and hyperthecosis.
项目摘要 我们的新研究表明,雄激素受体(AR)和AR作用的调节因子共阻遏物, COUPTF-II/NR 2F 2在小鼠卵泡膜细胞和正常人卵泡膜细胞中共表达 骑自行车和PCOS患者。小鼠体内暴露于雄激素导致卵泡膜细胞的显著变化 形态学和基因表达谱,其中最显著的是血管细胞的显著诱导, 粘附分子1(Vcam 1)。最近的挑衅性证据表明,在小鼠卵泡膜中选择性地破坏AR, 细胞阻止雄激素介导的PCOS表型,Vcam 1的诱导为 AR在卵泡膜细胞中的重要作用。从PCOS妇女繁殖的卵泡膜细胞表达更高水平的 与正常卵泡膜细胞相比,VCAM 1和CYP 17 A1升高,进一步支持了VCAM 1和CYP 17 A1升高的观点。 雄激素导致PCOS和卵泡膜增生症中卵巢功能改变和功能障碍。基于 这些令人信服的观察结果,我们假设升高的雄激素改变了卵泡膜细胞的AR调节, 导致细胞和分子事件发生特异性变化的功能,包括诱导Vcam 1, 是PCOS和卵泡膜增生症中卵巢功能障碍的基础和/或促成因素。我们建议使用基因- 改良的小鼠模型,从正常周期和PCOS卵巢分离的卵泡膜细胞,以及最先进的 分子和细胞技术,以实现三个具体目标。 具体目标1:确定破坏Ar、Nr 2f 2或Vcam 1的细胞和分子后果 选择性地在体内小鼠卵泡膜/基质细胞中和在来自正常循环的人卵泡膜细胞中, PCOS女性文化 具体目标2:确定分子和细胞事件以及对雄激素的反应, 当AR、NR 2f 2或Vcam 1在小鼠和人卵泡膜/基质中选择性过表达时, 细胞 具体目标3:确定雄激素诱导卵泡膜细胞中Vcam 1的分子机制 如果炎症因子和细胞是VCAM 1表达的关键, 这些研究的结果将为雄激素、AR、NR 2F 2和VCAM 1 通过确定哪些细胞事件和分子途径被选择性改变来影响卵巢功能障碍 在卵泡膜细胞中通过不同水平的AR受体激活。通过结合强大的突变小鼠模型和 充分表征的人类卵泡膜细胞,调节雄激素作用的新策略以及 将建立女性雄激素过多,并提供新的诊断标志物和治疗方法。 多囊卵巢综合征和卵泡膜增生症的治疗目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JoAnne Stewart Richards其他文献

JoAnne Stewart Richards的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JoAnne Stewart Richards', 18)}}的其他基金

Novel Aspect of Androgen Action in Ovarian Cell Function and Dysfunction
雄激素在卵巢细胞功能和功能障碍中作用的新方面
  • 批准号:
    10415947
  • 财政年份:
    2019
  • 资助金额:
    $ 32.66万
  • 项目类别:
Novel Aspect of Androgen Action in Ovarian Cell Function and Dysfunction
雄激素在卵巢细胞功能和功能障碍中作用的新方面
  • 批准号:
    10640129
  • 财政年份:
    2019
  • 资助金额:
    $ 32.66万
  • 项目类别:
Novel Aspect of Androgen Action in Ovarian Cell Function and Dysfunction
雄激素在卵巢细胞功能和功能障碍中作用的新方面
  • 批准号:
    10006016
  • 财政年份:
    2019
  • 资助金额:
    $ 32.66万
  • 项目类别:
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
类固醇激素调节卵巢癌的进展和转移
  • 批准号:
    8923209
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
类固醇激素调节卵巢癌的进展和转移
  • 批准号:
    9538594
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:
Mechanisms Controlling Divergent Fates of Ovarian Follicles and Fertility
控制卵巢卵泡和生育力不同命运的机制
  • 批准号:
    8694652
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:
Mechanisms Controlling Divergent Fates of Ovarian Follicles and Fertility
控制卵巢卵泡和生育力不同命运的机制
  • 批准号:
    9273274
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:
Mechanisms Controlling Divergent Fates of Ovarian Follicles and Fertility
控制卵巢卵泡和生育力不同命运的机制
  • 批准号:
    9527155
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:
Mechanisms Controlling Divergent Fates of Ovarian Follicles and Fertility
控制卵巢卵泡和生育力不同命运的机制
  • 批准号:
    9070506
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
类固醇激素调节卵巢癌的进展和转移
  • 批准号:
    8756182
  • 财政年份:
    2014
  • 资助金额:
    $ 32.66万
  • 项目类别:

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 32.66万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 32.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了